TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Brief Summary: The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia.

The secondary objective of the study is to assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD). To determine whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia. To evaluate whether memantine delays or decreases the emergence of parkinsonism in frontotemporal dementia.

The tertiary objective of the study is to determine whether treatment with memantine affects changes in weight


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): 2
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Multi-center, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are on Dialysis
Brief Summary: This 2 arm study will evaluate the efficacy of intravenous Mircera treatment for the correction of anemia in patients with chronic kidney disease who are on dialysis. Patients will be randomized to receive either Mircera 0.6 micrograms/kg i.v. every 2 weeks, or epoetin 3 times per week i.v. according to approved treatment recommendations. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
B: Arm Label: ESAs 1 low dose; Type: EXPERIMENTAL; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Arm Label: ESAs 2 high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 1 low dose | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 2 high dose
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: Correction Phase: CERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Arm Label: Correction Phase: Epoetin Beta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]; Assigned to Arm(s): Correction Phase: CERA | Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): Correction Phase: Epoetin Beta

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Multi-center, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are on Dialysis
Brief Summary: This 2 arm study will evaluate the efficacy of intravenous Mircera treatment for the correction of anemia in patients with chronic kidney disease who are on dialysis. Patients will be randomized to receive either Mircera 0.6 micrograms/kg i.v. every 2 weeks, or epoetin 3 times per week i.v. according to approved treatment recommendations. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
B: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: Correction Phase: CERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Arm Label: Correction Phase: Epoetin Beta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]; Assigned to Arm(s): Correction Phase: CERA | Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): Correction Phase: Epoetin Beta

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease
Brief Summary: Pluricentric randomized study comparing two therapeutic strategies at beginning of Crohn's disease: early immunosuppressants (prescription within the six first months following diagnosis) vs. conventional strategy (immunosuppressants given only in case of steroid failure, in a selected group of patients being at high risk of disabling course. The hypothesis is that immunosuppressants given early may improve the disease course during the 3 following years in this subset of patients.


Options:
A: Arm Label: Adacolumn; Type: ACTIVE_COMPARATOR; Interventions: Device: Adacolumn | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Adacolumn; Assigned to Arm(s): Adacolumn | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
B: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
C: Arm Label: control = conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immunossuppresive treatment; Type: EXPERIMENTAL; Interventions: Drug: early immunosuppressants (azathioprine, methotrexate) | Intervention Type: DRUG; Name: early immunosuppressants (azathioprine, methotrexate); Assigned to Arm(s): Immunossuppresive treatment
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease
Brief Summary: Pluricentric randomized study comparing two therapeutic strategies at beginning of Crohn's disease: early immunosuppressants (prescription within the six first months following diagnosis) vs. conventional strategy (immunosuppressants given only in case of steroid failure, in a selected group of patients being at high risk of disabling course. The hypothesis is that immunosuppressants given early may improve the disease course during the 3 following years in this subset of patients.


Options:
A: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
C: Arm Label: control = conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immunossuppresive treatment; Type: EXPERIMENTAL; Interventions: Drug: early immunosuppressants (azathioprine, methotrexate) | Intervention Type: DRUG; Name: early immunosuppressants (azathioprine, methotrexate); Assigned to Arm(s): Immunossuppresive treatment
D: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance
Brief Summary: The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin.


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin
B: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin
D: Arm Label: Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Brief Summary: The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN). A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.


Options:
A: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
B: Arm Label: Afatinib (BIBW 2992); Type: EXPERIMENTAL; Interventions: Drug: Afatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Afatinib; Assigned to Arm(s): Afatinib (BIBW 2992)
C: Arm Label: ARM 1 CRT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin | Arm Label: ARM 2 PRT; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): ARM 2 PRT | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): ARM 1 CRT
D: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anesthésie Totale Intraveineuse en " Boucle d'Asservissement " guidée Par l'Index Bispectral : Effet de l'Adjonction de Protoxyde d'Azote (Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia)
Brief Summary: The main objective of the study is to analyze the influence of nitrous oxide on propofol and remifentanil requirements.


Options:
A: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: air | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nitrous oxide | Intervention Type: DRUG; Name: air; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nitrous oxide; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
D: Arm Label: 70% Nitrous Oxide; Type: OTHER; Interventions: Other: Nitrous Oxide | Arm Label: No Nitrous Oxide; Type: OTHER; Interventions: Other: No Nitrous Oxide | Intervention Type: OTHER; Name: Nitrous Oxide; Assigned to Arm(s): 70% Nitrous Oxide | Intervention Type: OTHER; Name: No Nitrous Oxide; Assigned to Arm(s): No Nitrous Oxide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recurrent Throat Infections and Tonsillectomy
Brief Summary: The purpose of this study is to find out if tonsillectomy reduces the short-term risk of having an objectively confirmed (sequential changes in serum crp and procalcitonin levels) delayed pharyngitis episode among patients suffering from recurrent pharyngitis episodes. Other aims are to find out the effect of tonsillectomy to reduce the number of pharyngitis episodes or symptoms. Still, the possible disadvantages of tonsillectomy and changes in the quality of life after tonsillectomy among these patients are examined.


Options:
A: Arm Label: Adenotonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy | Arm Label: Adenotonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillotomy | Intervention Type: PROCEDURE; Name: Adenotonsillectomy; Assigned to Arm(s): Adenotonsillectomy | Intervention Type: PROCEDURE; Name: Adenotonsillotomy; Assigned to Arm(s): Adenotonsillotomy
B: Intervention Type: PROCEDURE; Name: (adeno)tonsillectomy; Assigned to Arm(s): N/A
C: Arm Label: Electrocautery tonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Debrider tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Laser tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Intervention Type: PROCEDURE; Name: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy; Assigned to Arm(s): Debrider tonsillotomy, Electrocautery tonsillectomy, Laser tonsillotomy
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy | Intervention Type: PROCEDURE; Name: Tonsillectomy; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HELPING HANDS: a Comparison of Short- and Long Term Effects of Alternative Strategies for Promoting Hand Hygiene in Hospital Nurses.
Brief Summary: Hand hygiene prescriptions are the most important measure in the prevention of hospital acquired infections. Yet compliance rates are generally below 50% of all opportunities for hand hygiene adherence. This study will test the short- and long term effects of two strategies for promoting hand hygiene in hospital nurses


Options:
A: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy
B: Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Disinfectant rubbing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Disinfectant rubbing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Disinfectant rubbing; Assigned to Arm(s): Disinfectant rubbing
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Face mask | Intervention Type: DEVICE; Name: control; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Face mask; Assigned to Arm(s): 1
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HELPING HANDS: a Comparison of Short- and Long Term Effects of Alternative Strategies for Promoting Hand Hygiene in Hospital Nurses.
Brief Summary: Hand hygiene prescriptions are the most important measure in the prevention of hospital acquired infections. Yet compliance rates are generally below 50% of all opportunities for hand hygiene adherence. This study will test the short- and long term effects of two strategies for promoting hand hygiene in hospital nurses


Options:
A: Arm Label: 1; Type: N/A; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): 1
B: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
D: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit

Answer: B